EP0202222A1 - Tissue re-calcification product - Google Patents
Tissue re-calcification productInfo
- Publication number
- EP0202222A1 EP0202222A1 EP19850900341 EP85900341A EP0202222A1 EP 0202222 A1 EP0202222 A1 EP 0202222A1 EP 19850900341 EP19850900341 EP 19850900341 EP 85900341 A EP85900341 A EP 85900341A EP 0202222 A1 EP0202222 A1 EP 0202222A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- mixture
- silica
- recited
- elemental
- potassium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
Definitions
- This invention is concerned with a novel combination of organic nutrients which is highly useful in the re-calcifi ⁇ cation of calcium-depleted tissues and, in particular, which is useful in replacing the so-called cortical boney matrix of the bone that constitutes the middle layer in the structure of the bone.
- Such calcium depletion is commonly caused by such phenomenon as aging., malnutrition, and injury to the bone per se.
- the present invention comprises a combination of natur ⁇ ally occurring silica such as vegetal silica which includes the compound silicon dioxide; and commonly occurring potassium such as potassium gluconate, the Combination of which is in approximately equal parts.
- the combination is employed as a dietary supplement; thereby; the resulting elemental potassium acts to promote absorption of the elemental silicon into the bloodstream.
- the elemental silicon then, together with carbon derived from normal biological processes (the breakdown of carbohy ⁇ drates) , serves in a catalytic transmutational function in order to bring about the deposition of calcium into the areas
- Mineral-containing mixtures in accordance with the pre ⁇ sent invention include a physical admixture of herbal silica and elemental potassium (K) .
- her ⁇ bal silica is derived in the form of vegetal silica from the equisetum species of plant.
- the chemical formula for the vegetal silica is the same as that for inorganic silicon di ⁇ oxide (Si0 2 ) •
- elemental potassium in the form of potassium glu- conate. It is to be appreciated that there are other sources from which elemental potassium may be derived, e.g., potassium biocarbonate and other naturally occurring products such as kelp which is rich in elemental potassium. It is contemplated that equal quantities of vegetal sil and potassium gluconate will be mixed and sold as a dietary supplement, this mixture containing neither sugar, starch, artificial coloring nor pre ⁇ servatives.
- Another ingredient that may be added is an analgesic.
- the sole function of the elemental potassium is to promote the absorption of the silica into the bloodstream; that is, the only function of the potas ⁇ sium is to act as a carrier of the silica into the bloodstream.
- the silica Once the silica has entered the bloodstream, it will separate into its components of silicon and oxygen. After this has occurred, the silicon will co-act with free carbon in the bloodstream (this carbon having been derived from normal met ⁇ abolic processes including the breakdown of hydrocarbons) in order to jointly act as a transmutational catalyst to enhance the formation of calcium within the bones and, as noted, to particularly enhance the re-calcification of the comical boney matrix (the middle layer) of the bones.
- a combination of free silicon and carbon will serve as a cat ⁇ alyst to enable depleted bone tissue to become re-calcified.
- the chemistry herein involved is essentially identical to that as which occurs in the formation of limestone as well ⁇ in certain organic processes including the formation of calcium within the shells of eggs of aieves (the bird family) .
- silicon and carbon have been found to perform a useful catalytic function in the enhancement of calcium deposition in bones in the human body.
- the selection of a 500 mg level for the vegetal silica and potassium gluconate is based upon established safe levels of said ingredients.
Abstract
Un agent de recalcification agit sur des tissus osseux humains. L'agent de recalcification comprend un mélange de silice végétale et de gluconate de potassium.A recalcification agent acts on human bone tissue. The recalcifying agent comprises a mixture of vegetable silica and potassium gluconate.
Description
Tissue Re-calcification Product
BACKGROUND OF THE INVENTION
This invention is concerned with a novel combination of organic nutrients which is highly useful in the re-calcifi¬ cation of calcium-depleted tissues and, in particular, which is useful in replacing the so-called cortical boney matrix of the bone that constitutes the middle layer in the structure of the bone. Such calcium depletion is commonly caused by such phenomenon as aging., malnutrition, and injury to the bone per se.
To the knowledge of the inventor, there does not exist any patented prior art which could be deemed to be a techno¬ logical equivalent of the present combination and/or method, or that is otherwise pertinent to the present invention.
Possibly relevant publications include the following:
1. Organic and Biological Chemistry Philip S. Chen, New York, 1968
2. Continuous Creation;
Routledge et Kegan, Paul Londres, 1950
3. Calcification et Transmutations Biologigues. Paris 1966
4. The Nature of Substance Vincent Stuart Condon, 1966
5. Silicemie et Calcification. Academy Suisse des Science des Medicine. Bale, 1956.
6. Submolecular Biology. Szent Gyorgyl. Paris, 1960
7. Le Calcium et ca Vie •Stockowski. Paris, 1960
8. Encyclopedia Pelle Medicine Nouve Codispote. Minerva Medica. Torino 1972
9. Merck Manual, 12th Edition Merck, Sharp & Doh e Research Labs., N.J. 1973
Relevant areas of classification are believed to be U. S. Class 252, Sub-class 1; U. S. Class 426, Sub-class 74; and U. S. Class 424, Sub-class 44.
SUMMARY OF THE INVENTION
The present invention comprises a combination of natur¬ ally occurring silica such as vegetal silica which includes the compound silicon dioxide; and commonly occurring potassium such as potassium gluconate, the Combination of which is in approximately equal parts. The combination is employed as a dietary supplement; thereby; the resulting elemental potassium acts to promote absorption of the elemental silicon into the bloodstream.
The elemental silicon then, together with carbon derived from normal biological processes (the breakdown of carbohy¬ drates) , serves in a catalytic transmutational function in order to bring about the deposition of calcium into the areas
of the cortical boney matrix that have been depleted of cal¬ cium.
It is accordingly an object of the present invention to provide a dietary supplement that will enhance the formation of calcium in decalcified bone structure.
The above and yet further objects and advantages of the present invention will become apparent from the hereinafter set forth Detailed Description of the Preferred Embodiment, and the appended Claims.
DESCRIPTION OF THE PREFERRED EMBODIMENT OF THE INVENTION
Mineral-containing mixtures in accordance with the pre¬ sent invention include a physical admixture of herbal silica and elemental potassium (K) . In a preferred embodiment, her¬ bal silica is derived in the form of vegetal silica from the equisetum species of plant. The chemical formula for the vegetal silica is the same as that for inorganic silicon di¬ oxide (Si02) •
Mixed, preferrably in equal quantity with the vegetal silica, is elemental potassium in the form of potassium glu- conate. It is to be appreciated that there are other sources from which elemental potassium may be derived, e.g., potassium biocarbonate and other naturally occurring products such as kelp which is rich in elemental potassium. It is contemplated that equal quantities of vegetal sil and potassium gluconate will be mixed and sold as a dietary supplement, this mixture containing neither sugar, starch, artificial coloring nor pre¬ servatives.
( _OMPI
In addition to the vegetal silica and potassium gluco- nate, may be added elemental calcium and elemental magnesium in order to further enhance the re-calcification function of the product. In this embodiment the listing of ingredients is as follows:
Vegetal silica 500 mg
Potassium gluconate . . 500 mg
Calcium 130 mg
Magnesium 78 mg
Another ingredient that may be added is an analgesic.
With regard to the operation of the present inventive mixture, it is to be understood that the sole function of the elemental potassium is to promote the absorption of the silica into the bloodstream; that is, the only function of the potas¬ sium is to act as a carrier of the silica into the bloodstream. Once the silica has entered the bloodstream, it will separate into its components of silicon and oxygen. After this has occurred, the silicon will co-act with free carbon in the bloodstream (this carbon having been derived from normal met¬ abolic processes including the breakdown of hydrocarbons) in order to jointly act as a transmutational catalyst to enhance the formation of calcium within the bones and, as noted, to particularly enhance the re-calcification of the comical boney matrix (the middle layer) of the bones.
In accordance with the present invention, it has been discovered that calcium depletion, whether caused by aging, malnutrition, or injury, can be reversed by creating in the bloodstream a proper catalytic combination; in this instance,
a combination of free silicon and carbon will serve as a cat¬ alyst to enable depleted bone tissue to become re-calcified.
The chemistry herein involved is essentially identical to that as which occurs in the formation of limestone as wellΛin certain organic processes including the formation of calcium within the shells of eggs of aieves (the bird family) . In this pror cess, silicon and carbon have been found to perform a useful catalytic function in the enhancement of calcium deposition in bones in the human body.
The selection of a 500 mg level for the vegetal silica and potassium gluconate is based upon established safe levels of said ingredients.
While there has been shown and described the preferred embodiment of the present invention, it will be understood that my invention may be embodied otherwise than as herein specifically described and that within such embodiment certain changes in the detail, quantities, and equivalents of the in¬ gredients may be made without departing from the underlying idea or principles of the invention within the scope of the appended Claims.
O PI
Claims
1. A dietary supplement for accomplishing a transmuta- tional re-calcification of calcium-depleted bone tissue, com¬ prising the mixture of:
(a) herbal silica; and
(b) elemental potassium
2. The re-calcification mixture as recited in Claim 1 in which said herbal silcia comprises vegetal silica.
3. The mixture as recited in Claim 2 in which said vege¬ tal silica comprises an equisetum species in plant.
4. The mixture recited in Claim 1, 2 or 3 in which said elemental potassium comprises potassium gluconate.
5. The mixture recited in Claim 4 in which said vegetal silica and elemental potassium are mixed in approximately equal quantities .
6. The mixture recited in Claim 5 further comprising an elemental calcium in about one-quarter of the weight of said vegetal silica.
7. The mixture recited in Claim 6 further comprising an elemental magnesium in approximately 15% of the weight of said vegetal silica.
8. The mixture recited in Claim 5 , 6 or 7, further com¬ prising an analgesic.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1984/001948 WO1986003121A1 (en) | 1984-11-27 | 1984-11-27 | Tissue re-calcification product |
Publications (1)
Publication Number | Publication Date |
---|---|
EP0202222A1 true EP0202222A1 (en) | 1986-11-26 |
Family
ID=22182344
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP19850900341 Withdrawn EP0202222A1 (en) | 1984-11-27 | 1984-11-27 | Tissue re-calcification product |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP0202222A1 (en) |
WO (1) | WO1986003121A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5035898A (en) * | 1987-11-27 | 1991-07-30 | Schering Corporation | Potassium/magnesium supplement |
ATE241917T1 (en) * | 1997-11-18 | 2003-06-15 | Energybalance Ag | MIXTURE OF MINERALS WITH IMPROVED FLAVOR |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1513298A (en) * | 1923-01-11 | 1924-10-28 | John W Turrentine | Therapeutic product and process of preparing same |
US4259315A (en) * | 1980-06-13 | 1981-03-31 | A. H. Robins Company, Inc. | Controlled release potassium dosage form |
-
1984
- 1984-11-27 WO PCT/US1984/001948 patent/WO1986003121A1/en unknown
- 1984-11-27 EP EP19850900341 patent/EP0202222A1/en not_active Withdrawn
Non-Patent Citations (1)
Title |
---|
See references of WO8603121A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1986003121A1 (en) | 1986-06-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5597585A (en) | Vitamin/mineral composition | |
Greenwood | Fluoride intoxication | |
Heppel | The electrolytes of muscle and liver in potassium-depleted rats | |
WO1994001006A2 (en) | Composition for use as a food or food supplement | |
Draper et al. | Nutrition and osteoporosis | |
KR880003620A (en) | Therapeutic Composition and Method | |
e Castro et al. | Hemolytic activity of thionin from Pyrularia pubera nuts and snake venom toxins of Naja naja species: Pyrularia thionin and snake venom cardiotoxin compete for the same membrane site | |
EP0202222A1 (en) | Tissue re-calcification product | |
BR0115104A (en) | Flavored Chocolate Flake | |
JPH0853358A (en) | Calcium composition excellent in absorbability | |
Givens | STUDIES IN CALCIUM AND MAGNESIUM METABOLISM: IV. EXPERIMENTS ON MAN | |
RU2220737C1 (en) | Curative-prophylactic composition "osteomaks-extra" for improvement of functional state of locomotor system | |
US5620709A (en) | Calcium containing composition from sea urchin with high oral bioavailability | |
KR20020091321A (en) | Calcium replenishers made from oyster shells and every kind of fruits and the methods of preparing them | |
RU2119756C1 (en) | Hematogen | |
JPH08205807A (en) | Production of aged, concentrated garlic solution free from foul breath | |
SU1549523A1 (en) | Food product | |
RU2030178C1 (en) | Adaptogenic agent | |
Deichmann et al. | Pain in jawbones and teeth in ciguatera intoxications | |
Macbride | Experimental Essays on Medical and Philosophical Subjects... | |
Jones | On Gravel, Calculus, & Gout: Chiefly an Application of Professor Liebig's Physiology to the Prevention and Cure of These Diseases | |
Funamoto et al. | Binding of strontium vs calcium to 17β-estradiol-induced proteins in the plasma of the goldfish Carassius auratus | |
CN1392263A (en) | Method for preparing easy body absorption protein-calcium by enzyme and health food produced by said protein-calcium | |
Broadhurst | Silicon’s elemental benefits | |
KR20210063539A (en) | Health supplements containing methyl sulfonyl methane and manufacturing method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB LI LU NL SE |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19861029 |